AI Startup Healx Looks to Find Repurposable Drugs for Rare Diseases
Summary
AI Startup Healx Looks to Find Repurposable Drugs for Rare Diseases Off the heels of a $56 million Series B funding round, Cambridge, UK-headquartered Healx is looking to partner with rare disease patient groups to advance treatments toward the clinic. Bloom tells us the platform was designed to use AI to augment human intelligence by better predicting what kind of repurposed drugs would work for a disease. To do this, Healnet uses several AI modalities, including natural language processing, and has demonstrated a 70 percent success rate in predicting preclinical outcomes, Bloom says. The advantage is that we find some really nonobvious connections.” The Series B funds also will be used to further develop the company’s AI platform and onboard new staff. Among the company’s current partners is the FRAXA Research Foundation, with which Healx is developing new treatments for fragile X syndrome, a genetic condition that causes intellectual disability.
Classifications
AskAI Classifications
LabelsLinked Companies
